ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ANAB AnaptysBio Inc

13.89
-0.08 (-0.57%)
24 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
AnaptysBio Inc NASDAQ:ANAB NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.08 -0.57% 13.89 12.50 14.46 14.59 13.82 13.91 238,479 22:00:00

Anaptys Announces Participation in November and December Investor Conferences

05/11/2024 9:15pm

GlobeNewswire Inc.


AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart


From Oct 2024 to Dec 2024

Click Here for more AnaptysBio Charts.

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences:

Guggenheim's Inaugural Healthcare Innovation Conference, Boston, MA

  • Format – Fireside chat and one-on-one investor meetings
  • Date and Time – Wednesday, Nov. 13, 2024 at 1:30pm ET / 10:30am PT

Stifel 2024 Healthcare Conference, New York, NY

  • Format – Fireside chat and one-on-one investor meetings
  • Date and Time – Tuesday, Nov. 19, 2024 at 1:50pm ET / 10:50am PT

Piper Sandler 36th Annual Healthcare Conference, New York, NY

  • Format – Fireside chat and one-on-one investor meetings
  • Date and Time – Tuesday, Dec. 3, 2024 at 2:30pm ET / 11:30am PT

7th Annual Evercore HealthCONx Conference, Coral Gables, FL

  • Format – Fireside chat and one-on-one investor meetings
  • Date and Time – Wednesday, Dec. 4, 2024 at 1:45pm ET / 10:45am PT

Live webcasts of the fireside chats will be available on the investor section of the Anaptys website at http://ir.anaptysbio.com/events. Replays of the webcasts will be available for at least 30 days following the events.

About Anaptys

Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its pipeline includes two programs targeting co-inhibitory receptors: ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis and rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. It also has other antibodies in its portfolio, including ANB033, an anti-CD122 antagonist, in a Phase 1 trial and ANB101, a BDCA2 modulator, soon to enter clinical development. In addition, Anaptys has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, that has completed Phase 3 trials for the treatment of generalized pustular psoriasis, and etokimab, an anti-IL-33 antagonist that is Phase 2/3 ready. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an anti-PD-1 antagonist (Jemperli (dostarlimab-gxly)) and an anti-TIM-3 antagonist (cobolimab, GSK4069889). To learn more, visit www.AnaptysBio.com or follow us on LinkedIn and X.

Contact:Nick MontemaranoSenior Director, Investor Relations and Strategic Communications 858.732.0178investors@anaptysbio.com

1 Year AnaptysBio Chart

1 Year AnaptysBio Chart

1 Month AnaptysBio Chart

1 Month AnaptysBio Chart

Your Recent History

Delayed Upgrade Clock